Tenofovir alafenamide prevents mother-to-infant HBV transmission

tenofovir alafenamide prevents mother to infant hbv transmission

Sumary of Tenofovir alafenamide prevents mother-to-infant HBV transmission:

  • November 15, 2021 1 min read Source/Disclosures Published by: Source: Zeng QL.
  • Back to Healio Tenofovir alafenamide therapy was safe, well-tolerated and prevented the transmission of hepatitis B virus from pregnant mothers to infants, according to research presented at The Liver Meeting Digital Experience.
  • In a multicenter study, researchers aimed to investigate the safety and effectiveness of TAF therapy in preventing mother-to-child HBV transmission.
  • Enrolled mothers received either TAF (n = 103) or TDF (n = 104) according to patient preference and all infants received immunoprophylaxis.
  • For mothers, Zeng and colleagues evaluated perinatal adverse events, complications, ALT flare and changes in kidney function at delivery, postpartum month 3 and postpartum month 6. Infant safety assessments included evaluation of structural defects at birth, Apgar scores and abnormal conditions from birth to 7 months.
  • Mothers and infants were closely monitored until at least 7 months postpartum;
  • The most common adverse event was nausea which occurred in 29.1% and 31.7% of mothers and the most common maternal complication was premature rupture of membranes (12.6% and 13.5%).
  • They further observed no congenital defects among infants as well as normal physical and neurological development through follow-up;

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.